KIT and neoplasm: RTKs can initiate tumor growth (Bcr-abl in chronic myelogenous leukemia [9,10]) or sustain tumor survival (EGFRmut in non-small cell lung carcinoma [11,12] and c-Kit in gastrointestinal stromal tumors [13]).